GGrantIndex
Sort

53,477 grants matching addiction

Center for Biomedical Research Excellence, Epigenomics of Development and Disease

$2,060,766
Roxanne A Vaughan · University Of North Dakota · P20 · FY2016 · GM

TMP-301, A Negative Allosteric Modulator of type 5 metabotropic glutamate receptors (mGluR5), for Treatment of Cocaine Use Disorder

$2,060,520
Charles Daniel Meyers · Tempero Bio, Inc. · U01 · FY2022 · DA

Emory-MSSM-GSK-NIMH Collaborative Mood and Anxiety Disorders Initiative

$2,059,619
Helen S Mayberg · Emory University · U19 · FY2011 · MH

Illuminating neural coding mechanisms using in vivo calcium imaging in freely behaving mice

$2,059,500
Da-Ting Lin · National Institute On Drug Abuse · ZIA · FY2020 · DA

Center for Biomedical Research Excellence, Epigenomics of Development and Disease

$2,058,088
Roxanne A Vaughan · University Of North Dakota · P20 · FY2017 · GM

Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choice

$2,058,020
Charles Bradberry · National Institute On Drug Abuse · ZIA · FY2017 · DA

Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choice

$2,057,916
Charles Bradberry · National Institute On Drug Abuse · ZIA · FY2018 · DA

ELEVATE Center: Reduction of Maternal Morbidity from Substance Use Disorder in Utah

$2,056,330
Torri D Metz · University Of Utah · U54 · FY2024 · HD

NIDA Clinical Trials Network: Greater New York Node

$2,054,565
John P Rotrosen · New York University School Of Medicine · UG1 · FY2019 · DA

Frontal Striatal Systems and Dopamine in Normal and Pathological Behavior

$2,054,308
Bruno Averbeck · National Institute Of Mental Health · ZIA · FY2019 · MH

Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain

$2,050,367
James N Campbell · Centrexion Therapeutics Corporation · UG3 · FY2021 · NS

A Novel Opioid-Free Targeted Pain Control Method for Acute Post-Operative Localized Pain Related to Oral Surgical Procedures

$2,050,357
Rahul Jadia · Revbio, Inc. · R44 · FY2023 · DE

Indigenous Trauma & Resilience Research Center

$2,048,753
Jonathan David Geiger · University Of North Dakota · P20 · FY2022 · GM

Investigation On The Behavioral Effects And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.

$2,047,482
Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2025 · DA

TOBACCO DEPENDENCE AND RISK FACTORS FOR TREATMENT FAILUR

$2,047,370
Yale University · P50 · FY2001 · DA

HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)

$2,047,069
Stephen A Spector · University Of California, San Diego · UM1 · FY2021 · AI

Mechanisms Of Synaptic Plasticity In The Adult And Developing Nervous System

$2,046,880
Serena M Dudek · National Institute Of Environmental Health Sciences · ZIA · FY2012 · ES

Investigation On The Behavior And Related Neuro-Electrochemistry Of Potential Medications For The Treatment Of Substance Use Disorders.

$2,046,473
Gianluigi Tanda · National Institute On Drug Abuse · ZIA · FY2023 · DA

Florida Node Alliance of the Drug Abuse Clinic Trials Network

$2,046,113
Jose Szapocznik · University Of Miami School Of Medicine · U10 · FY2014 · DA

Sleep, opiate withdrawal and the N/OFQ - NOP system

$2,045,252
Thomas S Kilduff · Sri International · R01 · FY2019 · HL

Monitoring presynaptic release of neuropeptides in awake behaving animals

$2,045,242
Sung Han · Salk Institute For Biological Studies · RF1 · FY2022 · NS

14/24 The Healthy Brain & Child Development National Consortium

$2,045,138
Gretchen E. Bandoli · University Of California, San Diego · U01 · FY2024 · DA

Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choice

$2,043,910
Charles Bradberry · National Institute On Drug Abuse · ZIA · FY2019 · DA

TOBACCO DEPENDENCE AND RISK FACTORS FOR TREATMENT FAILUR

$2,043,273
Yale University · P50 · FY2002 · DA

Clinical Trials Network, Ohio Valley Node U10DA013732

$2,042,401
T John Winhusen · University Of Cincinnati · U10 · FY2014 · DA